Skip to main
CYBN

Cybin (CYBN) Stock Forecast & Price Target

Cybin (CYBN) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Cybin Inc. is advancing its clinical-stage pipeline with a focus on innovative therapies for neuropsychiatric conditions, notably through its Phase 3 programs CYB003 and CYB004, which are progressing towards significant data readouts in 2026. The company has demonstrated strong clinical execution and operational stability, alongside strategic partnerships, such as with ThermoFisher, that enhance its commercial readiness across its therapeutic candidates. Despite recent adjustments in launch timelines and share count due to financing, Cybin maintains a substantial potential upside, reflecting confidence in its development trajectory and financial positioning.

Bears say

The outlook for Cybin Inc. is predominantly negative due to several critical factors impacting its financial stability and growth potential. The company has recently adjusted its discounted cash flow (DCF) valuation period, leading to a decrease in the DCF-based price target from $70 to $45, primarily attributed to dilution from recent capital raises. Additionally, the inherent risks associated with developing neuropsychiatric products—such as the uncertainty of clinical trial outcomes, regulatory approval challenges, and difficulties in protecting intellectual property—further exacerbate the company's precarious position in achieving successful commercialization of its therapeutics.

Cybin (CYBN) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cybin and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cybin (CYBN) Forecast

Analysts have given Cybin (CYBN) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Cybin (CYBN) has a Strong Buy consensus rating as of Jan 1, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $49.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $49.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cybin (CYBN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.